Wall Street Zen cut shares of Altimmune (NASDAQ:ALT – Free Report) from a sell rating to a strong sell rating in a report released on Saturday,Wall Street Zen reports.
Other equities analysts have also issued reports about the company. Evercore reaffirmed an “outperform” rating on shares of Altimmune in a research note on Wednesday, September 23rd. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a report on Friday. HC Wainwright reissued a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. B. Riley Financial reissued a “buy” rating on shares of Altimmune in a research report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.33.
Read Our Latest Analysis on Altimmune
Altimmune Stock Down 5.2%
Shares of NASDAQ:ALT opened at $1.56 on Friday. The firm has a market cap of $303.45 million, a P/E ratio of -2.17 and a beta of 0.16. Altimmune has a 12-month low of $1.50 and a 12-month high of $6.44. The business has a fifty day simple moving average of $2.55 and a 200 day simple moving average of $3.13. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07.
Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Analysts predict that Altimmune will post -0.58 earnings per share for the current year.
Insider Buying and Selling at Altimmune
In other Altimmune news, CEO Jerome Durso acquired 30,700 shares of the stock in a transaction dated Friday, November 13th. The stock was purchased at an average cost of $1.62 per share, with a total value of $49,734.00. Following the transaction, the chief executive officer owned 93,200 shares in the company, valued at approximately $150,984. The trade was a 49.12% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders bought 50,700 shares of company stock valued at $82,334. Company insiders own 1.60% of the company’s stock.
Institutional Investors Weigh In On Altimmune
Several large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC increased its holdings in Altimmune by 21,755.0% in the third quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock worth $25,000 after purchasing an additional 8,702 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Altimmune in the third quarter valued at approximately $28,000. IPG Investment Advisors LLC bought a new position in shares of Altimmune during the 3rd quarter worth approximately $29,000. Quantinno Capital Management LP bought a new position in shares of Altimmune during the 1st quarter worth approximately $33,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Altimmune during the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 78.05% of the company’s stock.
Altimmune Company Profile
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Further Reading
- Five stocks we like better than Altimmune
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
